

Freedom of Information Request	FOI 23-295	4th July 2023
--------------------------------	------------	---------------

I have a freedom of information query regarding the use of Biologic medicines in gastroenterology. Could you please answer the following two questions:

Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- **Adalimumab - Humira**
- **Adalimumab Biosimilar**
- **Filgotinib**
- **Golimumab**
- **Infliximab - Remicade**
- **Infliximab Biosimilar**
- **Ozanimod**
- **Tofacitinib**
- **Upadacitinib**
- **Ustekinumab**
- **Vedolizumab**
- **Vedolizumab Injections ONLY (pre-filled pens or syringes)**

The Health Board is only able to provide the information by quantity and not by patient. Please find below the quantities dispensed via hospital pharmacies for 'gastroenterology only' for any condition for the period March 2023 – May 2023.

Drug	Quantity
ADALIMUMAB (AMGEVITA) 40 mg in 0.8mL Pre-Filled Pen 2 Pre-Filled Pen Pack	725
ADALIMUMAB (AMGEVITA) 40 mg in 0.8mL Pre-Filled Syringe 2 Pre-Filled Syringe Pack	7
ADALIMUMAB (HUMIRA) 40 mg in 0.4mL Pre-Filled Pen 2 Pre-Filled Pen Pack	17
ADALIMUMAB (IMRALDI) 40 mg in 0.8mL Pre-Filled Pen 2 Pre-Filled Pen Pack	3
FILGOTINIB 200 mg Tablets 30 Tablet Pack	10
INFLIXIMAB (FLIXABI) 100 mg Intravenous Infusion 1 Vial Pack	1492
INFLIXIMAB (INFLECTRA) 100 mg Intravenous Infusion 1 Vial Pack	14
TOFACITINIB 10 mg Tablets 56 Tablet Pack	2

TOFACITINIB 5 mg Tablets 56 Tablet Pack	7
USTEKINUMAB (STELARA) 130 mg in 26mL Intravenous Infusion 1 Vial Pack	22
USTEKINUMAB (STELARA) 90 mg in 1mL Pre-Filled Syringe 1 Pre-Filled Syringe Pack	127
VEDOLIZUMAB (ENTYVIO) 108 mg in 0.68mL Pre-Filled Pen 1 Pre-Filled Pen Pack	484
VEDOLIZUMAB (ENTYVIO) 108 mg in 0.68mL Pre-Filled Syringe 1 Pre-Filled Syringe Pack	4
VEDOLIZUMAB (ENTYVIO) 300 mg Intravenous Infusion 1 Vial Pack	271

Q2. Does your trust participate in clinical trials for the treatment of Ulcerative Colitis? If so, please provide the total number of patients taking part in any Ulcerative Colitis study.

The Health Board currently has two open studies which include patients with Ulcerative Colitis as follows:

1. An observational study with 72 patients (which includes both Ulcerative Colitis and Crohns disease patients). Recruitment has ended.
2. A registry recruiting both Ulcerative Colitis and Crohns disease patients. currently has 17 participants.